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CLINICAL OUTCOMES IN THE MANAGEMENT OF IRON DEFICIENCY 
ANEMIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE 
 
KRISHANTH MANOKARAN 
ABSTRACT 	
INTRODUCTION: Anemia is a frequent complication in patients with inflammatory 
bowel disease (IBD). The inflammation observed in IBD negatively impact absorption of 
iron. This could lead to increased hospitalizations, affect growth and development, and 
decrease overall quality of life. This is especially pronounced in the pediatric population. 
The screening and treatment of iron deficiency anemia (IDA) varies between centers, and 
as a result, roughly 40-60% of pediatric IBD patients are iron deficient.  
OBJECTIVES: The objective of this study is to assess the efficacy and safety profile of 
intravenous and enteral iron therapy in a population of iron deficient patients with IBD. 
The secondary aim of this study is to determine if oral or intravenous iron therapy can 
improve hematologic and iron parameters. We will also examine the longitudinal changes 
in gastrointestinal (GI) symptoms and quality of life in patients receiving oral and 
intravenous iron supplementation.   
METHODS: We conducted a prospective cohort study in pediatric patients with IBD 
admitted to the inpatient GI service at Boston Children’s Hospital from 09/05/2017 to 
03/05/2018. Forty-six IBD patients were screened, and twenty-nine (63%) were identified 
		 vi 
as iron deficient and were consented for data collection through chart review and 
administration of the IMPACT-III quality of life questionnaire.  
RESULTS: Out of the twenty-nine IBD patients, eighteen (62%) received intravenous 
iron, seven (24%) received oral iron, and four (14%) were untreated and served as 
controls. The mean change in hemoglobin in patients receiving parenteral, oral, or no iron 
therapy was 1.6g/dl±0.5, 1.1g/dl±0.4, and 0.2g/dl±0.5, respectively. The change in 
hemoglobin was significant between the parenteral and oral iron group (P<0.05). The 
mean change in health-related quality of life scores in patients receiving parenteral or oral 
iron therapy was 11.6±11.4 and 3.8l±7.5, respectively.  
CONCLUSION: Our study demonstrates that intravenous iron therapy was more 
efficacious than oral iron in improving hematologic and iron parameters in IBD patients. 
This improvement was concomitant with higher scores on the IMPACT-III quality of life 
questionnaire, suggesting that iron supplementation improves health-related quality of 
life in IBD patients with iron deficiency anemia.  
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INTRODUCTION 
Iron  
Iron is an essential nutrient required by the human body for a wide variety of 
cellular processes. Notably, iron is required for synthesis of the heme molecule in 
hemoglobin as well as myoglobin, responsible for oxygen transport in muscle (Donovan, 
Roy, & Andrews, 2006). Iron also plays a functional role in the formation of numerous 
other enzymes involved in electron transfer and oxidation-reduction reactions (Donovan 
et al., 2006). Control of iron absorption in the body is tightly controlled through the level 
of expression and regulation of channels that reside in the membrane of small bowel 
enterocytes; dysregulation of iron metabolism can result in the formation of free radicals 
that attack cell membranes, proteins, and DNA leading to tissue damage (Waldvogel-
Abramowski et al., 2014). As such, we have developed elaborate protective extracellular 
and intracellular pathways including transferrin and ferritin proteins, which are found in 
plasma and within cells, respectively (Siah, Ombiga, Adams, Trinder, & Olynyk, 2006).  
The human body stores approximately 3-4g of iron (Abbaspour, Hurrell, & 
Kelishadi, 2014). The amount absorbed per day is roughly 10% of the amount ingested, 
and this is generally offset by daily losses through the desquamation of epithelial cells in 
the skin, GI tract, bile ducts, and blood loss during menstruation, which total around 1-
2mg per day (Abbaspour et al., 2014). Most dietary iron is absorbed in the proximal 
duodenum (Waldvogel-Abramowski et al., 2014). Here, brush-border ferric reductases 
reduce the insoluble ferric form (Fe3+) to the more bioavailable ferrous species (Fe2+) 
(Siah et al., 2006). Ferrous iron is able to cross the apical membrane of enterocytes via 
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carrier-mediated transport (divalent metal transporter, DMT1), and inside the enterocyte, 
iron binds to ferritin or mobilferrin (Siah et al., 2006). Unabsorbed iron that remains 
bound to ferritin at the end of the enterocyte life cycle is lost through desquamation into 
the feces (Donovan et al., 2006). Mobilferrin buffers intracellular iron, prevents 
formation of insoluble complexes, and facilitates the intracellular movement of iron to 
the basolateral membrane (Donovan et al., 2006). Once there, iron is transported by the 
carrier protein ferroportin and oxidized to the ferric form by the ferroxidase hephaestin 
and bound to transferrin in the blood (Figure 1) (Donovan et al., 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Mechanism of iron absorption in a single enterocyte  
                (Donovan et al., 2006) 
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Figure 2: Schematic of iron regulation through Hepcidin  
                (Donovan et al., 2006) 
Previous studies have demonstrated that hepcidin; a peptide hormone secreted by 
the liver, plays a central role in the regulation of iron absorption and systemic distribution 
(Waldvogel-Abramowski et al., 2014).  Hepcidin is a negative regulator of iron entry into 
plasma, and does so by binding to ferroportin and initiating its internalization and 
degradation in enterocyte lysosomes (Figure 2) (Waldvogel-Abramowski et al., 2014). 
Plasma hepcidin levels are regulated by various stimuli including circulating cytokines 
and tissue hypoxia, with inflammation correlating with higher levels of circulating 
hepcidin and lower plasma iron levels (Waldvogel-Abramowski et al., 2014). It is 
hypothesized that bioavailable iron is critical to pathogen propagation and may contribute 
to aberrant oxidant responses (Siah et al., 2006). Therefore with iron sequestration in 
enterocytes, circulating immune cells including tissue macrophages play an adaptive role 
in the body’s response to infection and stress (Siah et al., 2006).  Therefore, patients with 
chronic inflammatory disorders like inflammatory bowel disease (IBD) are at higher risk 
for developing iron deficiency anemia (Gasche, Lomer, Cavill, & Weiss, 2004).  
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Inflammatory Bowel Disease  
According to the latest report by the Crohn’s and Colitis Foundation (CCF), IBD 
affects approximately 1.6 million Americans, and nearly twenty-five percent of these 
patients are diagnosed prior to 20 years of age. IBD refers to the collection of chronic 
inflammatory disorders affecting the GI tract (Rufo & Bousvaros, 2006). While the 
pathogenesis of these diseases remain not fully understood, there are many studies that 
suggest that the disease is a result of an inappropriate inflammatory response to 
microbiota in the lumen of the GI tract (Matsuoka & Kanai, 2015). Certain environmental 
triggers, such as smoking, may interact with genetics to affect an individual’s 
predisposition to the development of IBD, which is typically characterized into two main 
subtypes: ulcerative colitis (UC) and Crohn disease (CD) (Matsuoka & Kanai, 2015). 
The inflammation observed in patients with CD generally involves the ileum and 
colon, but can affect any region of the GI tract, extending from the mouth to the anus and 
typically in a discontinuous distribution (Rufo & Bousvaros, 2006). The inflammation in 
CD is transmural, and can involve the whole bowel wall, including the mucosa, 
submucosa, muscularis, and serosal layers (Rufo & Bousvaros, 2006). Histologically, 
patients with CD can be identified by the identification of non-necrotizing tissue 
granulomas.  Phenotypically, CD can present as structuring or penetrating/perforating 
disease (DeRoche, Xiao, & Liu, 2014).  
In contrast, the inflammation observed in patients with UC typically begins in the 
rectum and extends in a contiguous fashion to involve varied portions of the colon (Rufo 
& Bousvaros, 2006). Unlike that observed in patients with CD, the inflammation in 
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Figure 3: Characteristics of ulcerative colitis and Crohn’s disease 
                 (Matsuoka & Kanai, 2015) 
patients with UC is confined to the mucosa (Figure 3), and can be further characterized 
based on the extent of anatomic involvement (Geboes et al., 2000). Colitis limited to the 
splenic flexure is termed, “left-sided/distal UC”; inflammation extending beyond the 
splenic flexure, and encompassing the entire colon in children is termed, “pancolitis”; 
inflammation limited to the rectum is termed, “proctitis” (Matsuoka & Kanai, 2015). 
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Figure 4: Gross and histological features of the colon in normal, UC, 
and CD conditions (DeRoche et al., 2014) 
There is a premium on distinguishing between different forms of IBD, as certain 
therapies may be more effective in treating either CD or UC (Rufo & Bousvaros, 2006).  
Despite the phenotypic differences in patients with CD and UC (Figure 4), there 
exists a group of patients in whom their histological, endoscopic, and radiologic findings 
may not be definitive in assigning a particular diagnosis, and these patients are 
characterized as having indeterminate colitis (Matsuoka & Kanai, 2015). The importance 
of this differentiation is especially pronounced in the pediatric population, as a delay in 
diagnosis and treatment may negatively impact growth and development (Rufo & 
Bousvaros, 2006).  
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Disease Indices: PUCAI vs. PCDAI   
Disease activity in pediatric patients with UC and CD can be assessed using the 
Pediatric Ulcerative Colitis Activity Index (PUCAI) and Pediatric Crohn’s Disease 
Activity Index (PCDAI), respectively (Rogler & Vavricka, 2015). These validated 
indices are composed of both subjective (patient or parent reported outcomes) and 
objective data (Rogler & Vavricka, 2015). The responses for each component of the 
PUCAI or PCDAI are graded and the summed score is used to characterize a particular 
patient’s disease activity at a particular point in time (Rogler & Vavricka, 2015).  
The PUCAI contains six items: abdominal pain, rectal bleeding, stool consistency, 
number of stools in the most recent 24 hour period, the presence or absence of nocturnal 
stools, and the impact of UC symptoms on a patient’s activity level (Table 1) (Turner et 
al., 2007). PUCAI score ranges from 0-85 with a score of <10 denoting remission, 10-34 
mild disease, 35-64 moderate disease, and 65-85 severe disease (Turner et al., 2007). A 
clinically significant response is defined as a PUCAI score change of ≥ 15-20 (Turner et 
al., 2007).  
The PCDAI contains twelve items including laboratory parameters: abdominal 
pain, general well-being, stools per day, hematocrit, erythrocyte sedimentation rate, 
albumin, weight, height at diagnosis, height at follow-up, abdomen, perirectal disease, 
and extraintestinal manifestations (Table 2) (Hyams et al., 2005). The PCDAI score 
ranges from 0-100 with a score of <10 consistent with inactive disease, 11-30 indicating 
mild disease, >30 moderate to severe disease, of which higher scores signify more active 
disease (Hyams et al., 2005).  
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Table 1: The Pediatric Ulcerative Colitis Activity Index (PUCAI) 
               (Turner et al., 2007) 
 The shortfall of this method of categorizing disease activity is that it relies on 
subjective reporting that is biased and may affect reproducibility in different settings 
(Turner et al., 2007). As such, no disease activity index can robustly characterize disease 
activity (or changes in disease activity) in all circumstances (Turner et al., 2007).  As 
such, clinicians continue to rely on objective lab measures, imaging, and endoscopy to 
assess disease activity (Hyams et al., 2005). Notably, the level of fecal biomarkers such 
lactoferrin and calprotectin, proteins derived from neutrophils, have been used as a non-
invasive method to assess intestinal inflammation and disease activity in children and 
adults (Rufo & Bousvaros, 2006). 
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Table 2: The Pediatric Crohn’s Disease Activity Index (PCDAI) 
               (Rufo & Bousvaros et al., 2006)  
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laboratory parameters, can expose iron storage deficiencies. 
When interpreting ferritin concentrations, however, it must 
be born in mind that inflammatory or malignant disease, liver 
disease and pregnancy may lead to false normal or elevated 
ferritin concentrations, and thus disguise an existing iron 
deficiency. A diagnostic panel consisting of ferritin, hemoglobin 
and CRP is in most cases adequate to confirm iron deficiency 
as the cause of anemia with acceptable diagnostic certainty. In 
unclear cases, these findings can be supplemented, depending 
on availability, with sTfR, ZPP, %HYPO and CHr. While these 
parameters, in contrast to ferritin, detect iron deficiency only 
at or beyond the stage of iron-deficient erythropoiesis, they are 
not impacted by inflammatory or malignant disease.
Treatment of iron deficiency anemia in IBD
Iron supplementation should be administered in all cases 
of manifest anemia [12]. Cases of iron deficiency without 
manifest anemia require an individualized approach according 
to clinical symptoms. In these cases, the timing and type of 
therapy is determined according to symptoms, etiology, degree 
of severity and dynamics of the hemoglobin decrease, and the 
comorbidities and risks of therapy [4]. Iron supplementation 
can be administered orally or intravenously. 
Oral iron administration
Oral iron supplementation has been the therapy of 
choice for many years. Despite recent recommendations of 
international expert guidelines, the use of IV iron preparations 
remains the subject of safety worries and is therefore still 
widely considered a last resort [12]. 
In IBD patients, iron(II) or iron(III) compounds may be 
administered orally in the absence of absolute indications for 
IV therapy (see below), and in IBD patients with mild anemia 
(Hb >10 g/dL) and inactive disease oral iron replacement 
can be used. This approach is supported by an the recently 
published study of Lomer et al [26] and our own data [27], 
which showed, that intestinal iron absorption is normal in 
quiescent or mildly active IBD patients.
However, as more than 90% of ingested iron remains 
unabsorbed, oral iron supplementation is associated with the 
frequent occurrence of gastrointestinal adverse effects, such as 
nausea, flatulence, diarrhea and gastric erosion. Furthermore, 
a potential for the exacerbation of IBD through the generation 
of reactive oxygen species (Fenton reaction) by non-absorbed 
iron has been revealed in both animal and human studies 
[28-30]. Upon initiation of oral iron supplementation, the 
patient’s response, tolerance and adherence should therefore 
be monitored. Patients showing insufficient response (Hb 
increase <2 g/dL within 4 weeks) or intolerance to oral iron, 
as well those with severe IDA (≤10 g/dL) and active disease 
(CRP >5 mg/L), should receive IV iron as first-line therapy [12].
Intravenous iron administration
IV iron therapy is recommended for iron-deficient patients 
who display intolerance or an inadequate response to oral 
preparations (i.e. insufficient increase in serum iron parameters 
within the first two weeks of treatment), severely anemic 
patients (Hb level <10 g/dL), those who have pronounced 
disease activity, and those undergoing treatment with 
erythropoiesis stimulating agents (ESAs) [12]. 
However, although the clinical efficacy and good safety 
Table 3 Laboratory findings in IDA, ACD and in mixed IDA/ACD
Laboratory Measures Normal IDA ACD IDA/ACD
Bone marrow iron 2-3 0-1 2 1-2
Serum iron 40-165 µg/L (Ļ) Ļ Ļ
Mean corpuscular volume 80-96 fl Ļ Ļor n Ļor n
Serum ferritin 16-350 µg/L Ļ Ĺ Ĺor n
Transferrin Ĺ Ĺ Ļ or n Ļ
Transferrin saturation 20-50% Ļ Ļ Ļ
*sTfR 0.8-2.2 mg/l Ĺ n or Ļ Ĺ or n
*sTfR-F index high (>2) high (>2) low (<1) high (>2)
CHr ≥ 29 pg ĻĻ n or Ļ Ļ
PHRC 1-5% >5% <5%
*Zinc protoporphyrin < 40 (µmol/ mol heme) >80 ≥80 ≥80
C-reactive protein < 5 mg/L n ĹĹ Ĺ
*values vary according to the different assays 
IDA, iron deficiency anemia; ACD, anemia of chronic disease; Chr, Reticulocyte hemoglobin content; PHRC, Percentage of hypochrome erythrocytes; sTfR, 
Serum transferrin receptor; sTfR-F, Soluble transferrin receptor/log ferritin
Table 3: Laboratory findings in IDA (Dignass et al., 2010)  
Iron Deficiency Anemia in IBD 
Anemia is a common complication observed in patients with IBD, and the most 
prevalent forms are iron deficiency anemia (IDA) and anemia of chronic disease (Kaitha, 
Bashir, & Ali, 2015). Previous studies have demonstrated that the largest contributor to 
anemia in patients with IBD is iron deficiency, and that approximately 40-70% of 
pediatric IBD patients have IDA (Dignass, Hartmann, & Stein, 2010). This high 
prevalence is likely the result of poor iron intake, malabsorption due to chronic intestinal 
inflammation, increased iron loss due to GI bleeding, and poor iron utilization (Dignass 
et al., 2010). IDA commonly presents clinically as fatigue, decreased physical stamina, 
and can have adverse effects on development and cognition (Murawska, Fabisiak, & 
Fichna, 2016). This leads to considerable deterioration in the patient’s quality of life and 
more hospitalizations (Murawska et al., 2016). Laboratory tests used in the diagnosis of 
IDA include serum iron, ferritin (a measure of iron stores), transferrin (a measure of 
ability to transport iron for use in RBC production), and reticulocyte hemoglobin content 
(indicator of current iron deficiency) (Table 3) (Murawska et al., 2016).  
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Treatment of Iron Deficiency Anemia in IBD 
Iron supplementation is used to treat IDA and can be administered orally or 
intravenously (IV) (Bonovas et al., 2016). Existing algorithms advocate for the use of 
oral or IV iron therapy depending on variables such as a patient’s clinical status, 
hemoglobin level, serum iron, ferritin, TSAT, reticulocyte hemoglobin content, and CRP 
(Figure 5) (Kaitha et al., 2015).  
In patients with IBD, iron (Fe2+ or Fe3+) compounds may be administered orally 
in patients with mild anemia and inactive disease; however, since more than 90% of 
ingested iron remains unabsorbed, oral iron therapy is associated with GI-related adverse 
effects such as nausea and diarrhea (Carrier, Aghdassi, Platt, Cullen, & Allard, 2001). 
There is also concern that unabsorbed iron in the lumen of the intestine may contribute to 
the generation of reactive oxygen species, leading an exacerbation of mucosal 
inflammation (Carrier et al., 2001). Thus, if the patient on oral iron supplementation 
shows intolerance, insufficient response (Hb increase <2g/dl within 4 weeks), has severe 
anemia (Hb≤10g/dl), and active disease (CRP>5mg/dl), IV iron is recommended (Carrier 
et al., 2001). 
Recent studies have demonstrated that IV iron may be a better approach than oral 
iron therapy for the management of IDA in pediatric patients with IBD (Reinisch, Staun, 
Bhandari, & Muñoz, 2013). IV iron allows for a greater delivery of iron in a shorter 
period of time, and is now the recommended method of iron treatment for patients with 
IBD in Europe (Geisser & Burckhardt, 2011). The effectiveness of treating patients with 
IDA has been measured by an increase in Hb concentration (≥2g/dl) (Danko & 
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Weidkamp, 2016). In a study using LMW IV iron dextran in children with IBD, 
researchers observed an average increase in Hb concentration of 2.9g/dl, demonstrating 
that IV iron dextran is generally a safe and effective method to treating IDA in pediatric 
patients that don’t tolerate oral iron therapy (Bonovas et al., 2016). Six IV iron 
preparations are currently commercially available: low-molecular weight (LMW) iron 
dextran, iron gluconate, iron sucrose, iron carboxymaltose, ferumoxytol, and iron 
isomaltoside (Cançado & Muñoz, 2011). Each of these preparation have differing 
maximum doses, infusion periods, adverse effects, and costs (Table 4) (Muñoz, Gómez-
Ramírez, & García-Erce, 2009). Despite this data, there are no concrete algorithms, and 
the use of IV iron therapy in the management of IDA in pediatric IBD patients still varies 
in practice with respect to provider and center (Stein & Dignass, 2013). 
Data from an as of yet unpublished study done at Boston Children’s Hospital 
(BCH) showed that a preponderance of pediatric patients admitted with IBD and IDA 
were not identified or treated for iron deficiency prior to their discharge. The 33% of 
patients treated for their IDA showed improved values in Hb and MCV levels compared 
to the patients not treated for their IDA.  
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Figure 5: Algorithm for the management of iron deficiency anemia in    
                patients with inflammatory bowel disease (Stein & Dignass, 2013) 
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over the previous 3–4 days. In hemodialysis patients it 
has been shown that CHr <29 pg more accurately pre-
dicts functional iron deficiency than the combined use 
of ferri tin and transferrin saturation,50 and that measure-
ment of CHr may also be able to predict the response to 
intravenous iron therapy 2–4 days after initiation.38
Based on the same concept is measuring the percent-
age of hypochromic red blood cells. An increase in the 
percentage of hypochromic red blood cells indicates a 
deficient iron supply of longer duration (because of the 
red blood cells’ lifetime of 120 days).44,47 As in the case 
of CHr, measuring the percentage of hypochromic red 
blood cells is particularly useful in the diagnosis of iron 
deficiency in the presence of inflammation.51 However, 
the utility of the test is limited as the percentage of hypo-
chromic red blood cells is dependent on the total number 
of red blood cells, which may vary with the length of 
storage time. Therefore, the red blood cell samples cannot 
be shipped to off-site laboratories. Tests for both CHr and 
the percentage of hypochromic red blood cells are widely 
available on many of the same automated hematology 
analyzers that perform complete blood counts and are 
therefore available without additional costs or time.47,51
Management of IDA in IBD
Iron supplementation should be administered in all 
cases of manifest anemia (Figure 4). An individualized 
approach is required for cases of iron deficiency without 
manifest anemia. The decision about the time and type of 
therapy is determined by the symptoms, etiology, sever-
ity, dynamics of the hemoglobin decrease, comorbidity 
and risks of therapy.32
The goal of therapy for IDA is to supply sufficient iron 
to increase hemoglobin levels >2 g/dl or increase them to 
normal values within 4 weeks, and to replenish storage iron 
(transferrin saturation >30%). Iron supplementation can 
be administered orally, intramuscularly or intravenously.
Oral iron therapy
Oral intake of Fe2+ or Fe3+ compounds is possible in 
patients with IBD if there are no absolute indications for 
intravenous therapy (see below). Oral iron preparations 
are available in the form of Fe2+ salts (for example, iron 
sulfate), Fe3+ polymaltose complex or heme iron poly-
peptides. Although oral administration of iron salts is 
inexpensive, it is less effective than parenteral administra-
tion; the estimated total iron requirement for a male 
patient weighing 70 kg with a hemoglobin level of 8.0 g/dl 
and a ferritin level of 15 μg/dl is calculated by the Ganzoni 
formula to be 1,500 mg.52 Based on an average iron absorp-
tion of 10 mg daily, assumed good compliance and no 
further blood losses, oral iron supplementation would 
have to be carried out for about 5 months. Given that 
the duodenum can maximally absorb 10–20 mg of iron 
per day, the use of high doses of iron is questionable.53 As 
success ful iron treatment has been shown with low doses, 
such as 15 mg iron per day,53–55 and there are no compara-
tive trials supporting high-dose iron therapy in IBD, low 
doses (for example, 50–100 mg) of iron are recommended, 
especially as these may lead to fewer adverse effects.
Three important points must be kept in mind when 
treating IBD-associated anemia with oral preparations: 
the additionally restricted absorption in these patients 
due to increased hepcidin levels;56 lack of adherence 
to therapy; and high iron requirement. In spite of an 
adequate hemoglobin increase, it is difficult or even 
impossible, especially in patients with IBD, to efficiently 
replenish the body’s iron stores.57
As more than 90% of ingested iron is not absorbed,8 
oral iron preparations frequently lead to the occurrence 
of gastrointestinal adverse effects, including nausea, flatu-
lence, diarrhea, gastric erosions and enteric siderosis.58,59 
Moreover, both rodent models56,60–62 and human studies63 
indicate that the generation of reactive oxygen species 
(Fenton reaction) by nonabsorbed iron can potentially 
lead to re-activation of IBD.64 There have also been reports, 
in rodent models at least, of an increase in dys plasia and 
carcinoma, which does not occur with intravenous iron 
administration.62,65,66 An inhibition of zinc absorption 
when taking oral iron preparations has also proved to be 
problematic, especially in patients with IBD, in which an 
increased zinc requirement has been shown.67
Intramuscular iron therapy
Until the late 1990s, intramuscular iron supplementation 
was recommended as a more effective and safer alter-
native to oral and intravenous iron supplementa tion, 
Serum ferritin levels <100 ng/ml and transferrin saturation <20%
or
Percentage of hypochromic red blood cells >5%
or
Reticulocyte hemoglobin content <29 pg
Confirm diagnosis of iron deficiency anemia
(serum ferritin levels, transferrin saturation, percentage of
hypochromic red blood cells, reticulocyte hemoglobin content)
Hb <12 g/dl (women) or <13 g/dl (men)
Hb <10 g/dl (women)
or <11 g/dl (men)
Hb 10–12 g/dl (women)
or 11–13 g/dl (men)
CRP levels normal High levels of CRP
(that is, severe
disease activity)
No efficacy
ESAs (in conjunction with
intravenous iron therapy)
Intravenous iron
(500–1,500 mg)
Oral iron
100 mg iron daily
Intolerance
No adherence
No efficacy
Figure 4 | Algorithm for the management of iron deficiency anemia in IBD. 
Abbreviations: CRP, C-reactive protein; ESA, erythropoiesis-stimulati g agent;  
Hb, hemoglobin. 
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profile of IV iron have been clearly demonstrated in a number of 
observational and controlled studies in UC and CD patients, many 
gastroenterologists are still apparently reluctant to administer 
iron intravenously, for fear of hypersensitivity reactions [31].  
There are now six IV iron preparations available which have 
a good safety record in other diseases (Table 4). Over the last 
decade, iron sucrose (IS) has become standard of care in IBD, 
due to its proven efficacy, wide availability and excellent safety 
record [32-38]. However, since a large number and frequency 
of applications is required (maximum dose 600 mg per week) 
and administration is relatively time-consuming (3.5 h for a 
500 mg dose), the practicality of IS for the achievement of 
high level iron repletion is limited.
A new option for iron supplementation is the recently-
approved, novel generation of so-called Type I IV iron 
preparations, which can be applied in high single doses 
(so-called “total dose infusions, TDi”). As yet, data in IBD 
patients are available only for low molecular weight (LMW) 
iron dextran preparations and ferric carboxymaltose. 
The efficacy and safety of LMW - iron dextran preparations 
(e.g. Cosmofer®) in IBD patients with IDA have been studied 
both in children [39] and in adults [40,41], demonstrating a 
significant hematopoietic response. However, iron dextrans 
have been associated with the occurrence of IgE-mediated 
anaphylactic reactions, reported in these studies to be 2-6% 
in spite of a successful test infusion [40,41]. LMW - iron 
dextran preparations allow the total iron dose to be given in 
only 1-2 infusions. However, administration of LMW-iron 
dextran at this dose level is time-consuming, taking some 
4-6 h. This not only inconvenient, but also results in loss of 
patient productivity.
Ferric carboxymaltose (Ferinject®), is a stable, 
macromolecular (150 kDalton) ferric hydroxide carboxymaltose 
complex which can be administered at a dose of up to 1000 mg 
in only 15 min. To date, safety and efficacy data regarding the 
IV administration of ferric carboxymaltose (FCM) are available 
for over 3,500 patients with IDA resulting from chronic kidney 
disease [42,43],  congestive heart failure [44,45], pregnancy, and 
postpartum [46,47]. In most of these trials, patients received 
FCM equivalent to an iron dose of ≤ 1000 mg (or 15 mg/kg in 
those weighing less than 66 kg) given as an infusion over ≤ 15 
min, with subsequent weekly infusions. Two randomized studies 
have confirmed the superiority of this new formulation in IBD 
patients, the first of these [48] showing the drug to be efficacious 
and well-tolerated when compared with oral iron, and the second 
demonstrating the efficacy and safety of the drug compared to 
iron sucrose in a multinational, randomized study including more 
than 550 patients [49]. Ferric carboxymaltose was considerably 
more effective in correcting anemia than iron sucrose; more 
patients on ferric carboxymaltose showed hemoglobin values 
increased by ≥20 g/L, or achieved normalization of hemoglobin 
levels, than with IS. Moreover, since FCM required a mean of 
only 2.1 15-min infusions, as opposed to 5.8 infusions of 1 
h duration in the iron sucrose group, it was also found to be 
Table 4 Preparations available for intravenous iron supplementation (April 2012)
Iron dextran 
(LMW)
Iron gluconate Iron sucrose Iron carboxy-
maltose
Ferumoxytol Iron
Isomaltoside
Molecular weight 165 kD 37.5 kD 43.3 kD 150 kD 731  kD 150 kD
Complex stability High Low Moderate High High High
Test dose required Yes No Yes No No No
Maximum  
approved dose
20 mg/kg BW 62.5 mg 200 mg*
7 mg/kg BW
1000 mg if patient 
weight > 66 kg
15 mg/kg b
510 mg 20 mg/kg BW
Maximum Infusion 
period
360 min 30 min 210 min 15 min 17 sec 15 min
Maximum single 
dose on injection
200 mg 62.5 mg 200 mg 500 mg 510 mg 200 mg
Minimum Infusion 
period
2 min 10 min 10 min Bolus 17 sec Bolus
Dose-related 
reactions
Hypotension, 
edema
Hypotension, 
edema
Hypotension, 
edema
None reported None reported None reported
Relative risk of 
severe side effects
Moderate Low Very low None reported Very low None reported
Costs per 500 mg 
(€)**
84-86 52-56 105-110 170-175 *** 170-175
*In most countries the dosage is fixed to 200 mg (label), in some countries 500 mg are approved
** in Germany August 2012
*** approved by the EMEA in April 2012, but not yet available 
LMW, low molecular weight
Table 4: A comparison of the types of iron supplementation  (Stein & Dignass, 2013)  
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Health-Related Quality of Life Metrics  
Health-related quality of life (HRQOL) has emerged as an important 
consideration in assessing the disease burden, as well as determining the efficacy of 
medical care (Abdovic et al., 2013). HRQOL aims to measure the patient’s perception of 
their health status and how their disease affects physical, emotional, and social well-
being, and can complement information from disease indices and objective measures to 
evaluate how the disease affects a patient’s life (Abdovic et al., 2013).  
In chronic disorders like IBD, the evaluation of quality of life is particularly 
important over the course of time as many areas of a patient’s functioning, beyond 
physical health, may be subject to disease-related impact (Habibi et al., 2017). Unique to 
pediatric patients with IBD is the pronounced effect on growth and psychosocial 
development (Habibi et al., 2017). There is currently more literature relating to HRQOL 
in adult patients with IBD than in the pediatric population (Ghosh & Mitchell, 2007). At 
present, the IMPACT-III and Pediatric Quality of Life Inventory (PedsQL) 
questionnaires are probably the most widely used metrics for determining HRQOL in 
children with IBD (Habibi et al., 2017).   
  The IMPACT-III was developed to study the HRQOL in children specifically 
with IBD, and is a self-reported measure with 35 questions organized within six domains: 
bowel symptoms (7 questions), emotional functioning (7 questions), social functioning 
(12 questions), treatment and interventions (3 questions), body image (3 questions), and 
systemic symptoms (3 questions) (Abdovic et al., 2013). The IMPACT-III uses a five-
point Likert scale ranging from 1 to 5 for all answers, and the outcome score ranges from 
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35 to 175, with higher scores suggesting improved function and a better quality of life 
(Abdovic et al., 2013).  
The Pediatric Quality of Life Inventory (PedsQL) questionnaire is a more generic 
measure and has been used to assess HRQOL in healthy children and those with acute 
and chronic health conditions (Ghosh & Mitchell, 2007). For patients with IBD, the 
PedsQL contains a Gastrointestinal Symptoms Module and General Well-Being Scale, 
which provide a score on GI symptom health and psychosocial health (Ghosh & Mitchell, 
2007). Participants rate the extent to which each item has been a problem for them during 
the past month on a five-point Likert scale ranging from zero (Never) to four (Almost 
Always) (Ghosh & Mitchell, 2007). The questions are reverse scored and linearly 
transformed to a 0 to 100 scale with higher scores suggesting a better quality of life 
(Ghosh & Mitchell, 2007). 
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OBJECTIVES 	
The primary objective of this study is to assess the efficacy and safety of 
parenteral and enteral iron therapy in a population of iron deficient patients with IBD 
receiving their care in an academic tertiary care center. The secondary aim of this study is 
to determine if oral or parenteral iron supplementation can improve hematologic and iron 
parameters (≥ 2 point increase in hemoglobin). We will also analyze and compare 
longitudinal changes in GI symptoms and quality of life in patients receiving IV and oral 
iron supplementation.  
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MATERIALS AND METHODS  
Study Design 
We conducted a prospective cohort study in pediatric IBD patients admitted to the 
inpatient gastrointestinal service at BCH that fit our criteria of iron deficiency from 
09/05/2017 to 03/05/2018. The inclusion criteria included patients with an established 
diagnosis of IBD, low hemoglobin levels (adjusted for age and gender), and iron 
deficiency defined as a reticulocyte hemoglobin of less than 27pg. Patients were excluded 
from our study if they had prior surgical history (including colectomy or small bowel 
resection), their primary GI provider did not recommend iron supplementation, the 
patient refused iron therapy, reticulocyte count was greater than 27pg, or if the patient 
had an infection.  
We screened 46 inpatients and identified 29 who met the inclusion criteria, of 
which 18 received IV iron therapy, 7 received oral iron therapy, and 4 were untreated. 
Fifteen patients completed HRQOL questionnaires and all patients had their laboratory 
and disease phenotype data abstracted from their medical record. This study was 
approved by the BCH institutional review board (IRB) under protocol # P00024515.  
  
Patient Selection 
Using Cerner Powerchart, we reviewed the Children’s Hospital GI inpatient list 
on a daily basis to identify patients with IBD that were admitted with laboratory studies 
consistent with IDA. Iron studies (reticulocyte count, ferritin, TIBC, and plasma iron) 
were included in the initial evaluation within the scope of standard of care. As clinically 
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indicated, guidelines for treatment with parenteral or enteral iron therapy was provided to 
pediatric house staff. Patients were consented to complete the relevant HRQOL 
questionnaires. Patients were approached in their hospital rooms to maintain privacy. 
After consent was obtained and questions completed, patients were given a unique study 
ID to preserve their anonymity during analysis. Patients were then approached during 
their follow-up ambulatory appointments to complete identical HRQOL measures.   
 
Study Data  
The data abstracted from the electronic medical record included patient 
demographics (date of birth, sex, race, ethnicity, IBD diagnosis), medications, serologic 
testing, activity scores (PUCAI and PCDAI), prior surgeries, and endoscopic studies. 
Laboratory data include complete blood count with differential, liver panel, inflammatory 
markers, and iron studies. HRQOL metrics were collected through administration of 
questionnaires. These data points were collected during their inpatient stay and at 
subsequent outpatient visits for twelve months. The percentage of IBD patients treated 
with IV or oral iron, and the response rate were measured and compared to those not 
receiving iron supplementation. Adverse reactions to iron therapy were also monitored. 
 
Data Collection 
A case report form (CRF) for this study was created using the Research Electronic 
Data Capture (REDCap), a secure web application for building and managing data 
collected from Powerchart. The CRF was built on this platform was HIPAA compliant, 
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easily modifiable, and permits multiple users to enter data into the forms. The CRF’s for 
this study include eight domains: demographic data, anthropomorphic measures, 
medications, labs, treatment decisions, colonoscopy report, PedsQL and IMPACT-III 
questionnaires. The information collected in the CRF is therefore a comprehensive data 
set, which can be used to both answer the questions posed in this study and serve as 
preliminary data in support of future lines of investigation.   
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Page 1 of 19Demographic Data
Study ID __________________________________
Medical Record Number __________________________________
Date __________________________________
((MM-DD-YYYY))
Encounter Number: __________________________________
Primary GI Provider's Name __________________________________
Inpatient Attending __________________________________
Inpatient Fellow __________________________________
DEMOGRAPHIC DATA
Date of Birth __________________________________
Gender Male Female
Ethnicity Hispanic or Latino
Not Hispanic or Latino
Unknown
Race (Check all that apply.) White
Black / African-American
Asian
Native American / Alaskan Native
Native Hawaiian / Other Pacific Islander
Other
Specify other race __________________________________
DIAGNOSIS at admission 
Diagnosis Crohn Disease
Ulcerative Colitis
Indeterminate Colitis
Crohn Disease Phenotype Fistula
Inflammatory
Stricture
Unsure
Ulcerative Colitis Phenotype Pancolitis
Left-Sided Colitis
Pancolitis
Date of Diagnosis __________________________________
(date of first colonoscopy)
Prior Surgery? Yes
No
Figure 6: CRF Demographic Data  
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If Yes, Prior Surgical History Colectomy
Short Bowel Resection
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Figure 7: CRF Anthropomorphic Measures and Medication Data  
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Page 4 of 19Medications
Date: __________________________________
Encounter Number: __________________________________
Is the patient already taking oral iron? Yes
No
Is the patient compliant with their oral iron? Yes, 50% or greater
No,  50% or less
How  long have they been taking their iron Less than one month
supplement? One month or more
Type of iron supplementation Ferrous Sulfate
Ferrous Gluconate
Other
Dose of oral iron __________________________________
((mg/day))
Concurrent Medications ASA
Immunomodulator
Steroids
Biologic
Other
Type of ASA medication Pentasa
Sulfazalizine
Lialda
Balsal
Apriso
Asacol
Rowasa
Canasa
Dose of ASA __________________________________
((mg/day))
Type of Immunomodulator 6MP
AZA
MTX
Dose of Immunomodulator __________________________________
((mg per day/week))
Type of Biologic Inflixmab
Adalimumab
Certolizomab
Ustekinumab
Vedolizamab
Dose of Biologic __________________________________
((mg/dose))
12/18/2017 4:06pm www.projectredcap.org
Confidential
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Page 3 of 19A thropomorphic Measures
BASELINE MEASURES
Date __________________________________
((MM-DD-YYYY))
Encounter Number: __________________________________
Height (cm) __________________________________
(_ _ _ cm)
Weight (kg) __________________________________
(_ _ _ . _ kg)
BMI __________________________________
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Page 6 of 19Labs
Date of Labs: __________________________________
Encounter Number: __________________________________
Was this an admission? Yes
No
WBC __________________________________
Hemoglobin __________________________________
Hematocrit __________________________________
MCV __________________________________
Platelets __________________________________
ESR __________________________________
Albumin __________________________________
CRP __________________________________
Ferritin __________________________________
TIBC __________________________________
Plasma Iron __________________________________
Reticulocyte Count __________________________________
Reticulocyte Hemoglobin __________________________________
Figure 8: CRF Lab and Treatment Decision Data 
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Radiology Report
normal abnormal
Upper
TI
Cecum
Ascending Colon
Transverse Colon
Descending Colong
Sigmoid Colon
Rectum
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Page 10 of 19Colonoscopy Report
Date: __________________________________
Encounter Number: __________________________________
Did the patient get scoped since the admission Yes (E + Cs)
(encounter 1) or since the last encounter? No
Date of Pathology Report __________________________________
Pathology Report
normal acute chronic granuloma other
Upper
TI
Cecum
Ascending Colon
Transverse Colon
Descending Colon
Sigmoid Colon
Rectum
Date of Endoscopy __________________________________
Endoscopic Report
normal abnormal
Upper
TI
Cecum
Ascending Colon
Transverse Colon
Descending Colon
Sigmoid
Rectum
Did the patient get any imaging done since admission Yes
or since last encounter? No
Date of Radiology Report: __________________________________
Radiology Data MRI
CT
UGI/SBT
Figure 9: CRF Colonoscopy Report Data 
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Please complete the survey below.
Thank you!
Date of visit: __________________________________
Encounter Number: __________________________________
PUCAI Yes
No
Abdominal Pain No pain [0]
Pain CAN be ignored [5]
Pain CANNOT be ignored [10]
Rectal Bleeding None [0]
Small amount (< 50%) [10]
Small amount (most stools) [20]
Large amount (>50%) [30]
Stool Consistency Formed [0]
Partially formed [5]
Completely unformed [10]
Number of Stools Per 24h 0-2 [0]
3-5 [5]
6-8 [10]
>8 [15]
Nocturnal Stools No [0]
Yes [10]
Activity Level No limitation [0]
Occasional limitation [5]
Severe restricted activity [10]
Sum of PUCAI __________________________________
((0-85))
abbreviated PCDAI Yes
No
Abdomen No tenderness, no mass [0]
Tenderness or mass w/o tenderness [5]
Tenderness and involuntary guarding and definite
mass [10]
Perirectal Disease None, asymptomatic [0]
Indolent fistula (1-2), scant drainage, no
tenderness [5]
Active fistula, drainage, tenderness, or abscess
[10]
Weight Weight gain or voluntary weight stable/loss [0]
Involuntary weight stable, weight loss (1-99%) [5]
Weight loss (10%) [10]
Figure 10: CRF PUCAI/PCDAI Data 
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Page 16 of 19Inpatient QoL Measure
Date of visit: __________________________________
Encounter Number: __________________________________
General well-being scale
About me: __________________________________
((0-24))
In general... __________________________________
((0-4))
GI Symptoms
Stomach pain and hurt: __________________________________
((0-24))
Stomach discomfort: __________________________________
((0-20))
Food and drink limits: __________________________________
((0-24))
Trouble swallowing: __________________________________
((0-12))
Heartburn and reflux: __________________________________
((0-16))
Nausea and vomiting: __________________________________
((0-16))
Gas and bloating: __________________________________
((0-28))
Constipation: __________________________________
((0-64))
Blood in poop: __________________________________
((0-8))
Diarrhea: __________________________________
((0-28))
Worry about going poop: __________________________________
((0-20))
Worry about stomach aches: __________________________________
((0-8))
Medicines: __________________________________
((0-16))
Communication: __________________________________
((0-20))
Figure 11: CRF PedsQL Data 
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Figure 12: CRF IMPACT-III Data 
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Page 18 of 19Inpatient Impact III
Date of visit: __________________________________
Encounter Number: __________________________________
Bowel symptoms __________________________________
(7-35)
Systemic symptoms __________________________________
(3-15)
Emotional functioning __________________________________
(7-35)
Social functioning __________________________________
(12-60)
Body image __________________________________
(3-15)
Treatments and interventions __________________________________
(3-15)
Total score __________________________________
(35-175)
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Table 5: Descriptive statistics of demographic variables (n=46)  
                  
RESULTS 
Patient Characteristics 
 Forty-six IBD patients (26 with CD and 20 with UC) were prospectively enrolled 
in this study. After initial screening, 15 patients (32%) were identified as not iron 
deficient, 29 patients (63%) were identified as iron deficient, and 2 patients (5%) did not 
have their iron studies completed in time to determine iron status. Of the 29 patients, 25 
received iron therapy (18 with intravenous and 7 with oral iron) and 4 patients were 
untreated due to being discharged before the suggestion of iron therapy could be made 
(Figure 13). The population of our study is 59% male, with an average age of 14.8 years 
(SD 3). The average IBD diagnosis duration was 3.3 years (SD 3.5). Eight out of the 29 
patients (28%) had a hemoglobin level <9g/dl and 4 patients (14%) had a reticulocyte 
hemoglobin <20pg. All the patients who completed questionnaires remained in the study. 
UC localization, CD type, and other demographic data are presented in Table 5.  	 		
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Figure 13: Flowchart of patient recruitment according to initial screening.  
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Figure 14: Change in hemoglobin after IV and oral iron therapy  
                  
Changes in Hemoglobin Level with Iron Therapy  
The change in hemoglobin level was observed in iron deficient patients with IBD 
who received either intravenous or oral iron therapy. The intravenous iron agents were 
INFeD and Venofer. The oral iron formulation used was ferrous sulfate. Patients 
identified as iron deficient but who were not treated with iron therapy were characterized 
as the control group, with hemoglobin levels assessed at baseline and follow-up. The 
mean change in hemoglobin in patients receiving IV iron, oral iron, or no iron therapy 
was 1.6g/dl±0.5, 1.1g/dl±0.4, and 0.2g/dl±0.5, respectively. The change in hemoglobin 
was significant between the IV iron and oral iron group (P<0.05) and IV iron and control 
group (P<0.005) (Figure 14).  
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Figure 15: Change in hemoglobin after IV iron therapy  
                  
Change in Hemoglobin Level with Intravenous Iron Therapy  
Next, we observed the change in hemoglobin level with the administration of the 
different intravenous iron agents, namely INFeD (LMW iron dextran) and Venofer (iron 
sucrose). No patients during our study received Ferrlecit (sodium ferric gluconate). All 
three formulations are currently on the BCH formulary, and the choice to use either agent 
was up to the discretion of the attending physician. A major difference is that INFeD 
enables more iron to be given at one sitting (upto 2 grams) whereas the other iron 
therapies (Venofer and Ferrlecit) only allow the administration of about 200mg per 
infusion. The mean change in hemoglobin in patients receiving INFeD or Venofer was 
1.85g/dl±0.64 and 1.31g/dl±0.34, respectively. The change in hemoglobin between the 
two agents was determined not to be statistically significant (P=0.068) (Figure 15).  
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Figure 16: Change in IMPACT-III score after IV and oral iron therapy 
                  
Changes in the HRQOL Measures with Iron Therapy 
The first HRQOL measure was taken before the administration of IV iron or oral 
iron therapy in the inpatient setting. The follow-up HRQOL measure was taken during 
their next outpatient visit. The IMPACT-III is a 35-question survey used to assess the 
HRQOL in patients with IBD. The outcome score ranges from 35 to 175, with higher 
scores suggesting a better quality of life. The mean change in IMPACT-III score in 
patients receiving IV or oral iron was 11.6±11.4 and 3.8l±7.5, respectively. The changes 
in IMPACT-III score between the two groups were not statistically significant (P=0.14).  
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 DISCUSSION 
  
Anemia is a common complication in patients with IBD and is likely the result of 
malabsorption (due to chronic inflammation impairing intestinal function), poor iron 
intake, increased iron losses (due to GI bleeding) and poor iron utilization (Schröder et 
al., 2005). IDA is common among children with IBD and could present as fatigue, 
decreased endurance, decreased sense of overall well-being, and when chronic can lead to 
particularly adverse effects on development and cognition (Lucendo et al., 2017). 
Evidently, treating iron deficiency has been shown to improve HRQOL in patients with 
chronic diseases (Rogler & Vavricka, 2015). The primary goal of this study was to assess 
the efficacy and safety profile of parenteral and enteral iron therapy in a population of 
iron deficient patients with IBD admitted to the inpatient gastrointestinal service at BCH 
from 09/05/2017 to 03/05/2018. We conducted this prospective study on 46 patients, of 
which 29 (63%) were identified as iron deficient. Of this subset, 18 were treated with IV 
iron, 7 with oral iron, and 4 who were not treated served as controls for this study.  
We identified IBD patients as iron deficient based on the results of their iron 
studies, which were taken during their inpatient stay. Since screening for iron deficiency 
falls within the scope of standard of care, these labs were requested directly to the 
inpatient team. Specifically, serum iron, ferritin, total iron-binding capacity (TIBC), and 
reticulocyte hemoglobin count (RH) were obtained. Patients with an RH of less than 27pg 
were identified as iron deficient. The choice of treating with intravenous or oral iron 
therapy was up to the discretion of the provider and patient. Those with a prior surgical 
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history (including colectomy or small bowel resection), suspected infection, or who 
refused iron therapy were excluded from our study.  
The standard outcome measure of efficacy in treatment of patients with IDA is an 
increase in hemoglobin concentration (Kaitha et al., 2015). In our study, patients given 
intravenous iron were shown to have a higher mean increase in hemoglobin (1.6g/dl±0.5) 
compared to patients given oral iron (1.1g/dl±0.4) (P<0.05). This can be attributable to 
the higher doses of iron administered intravenously than orally. The standard dose of oral 
iron (ferrous sulfate) was typically 325mg BID, while intravenous iron was given at 
doses as high as 1,743mg in one sitting. Even with lower intravenous iron doses, the lack 
of first pass effect and resulting 100% bioavailability allows for more iron to reach the 
bloodstream and be utilized in hemoglobin production.  
In a previous study employing IV iron dextran in pediatric patients with IBD, they 
reported an average increase in hemoglobin concentration of 2.9g/dl, demonstrating that 
total iron repletion with intravenous iron dextran infusion is generally a safe and effective 
method in treating IDA in children with IBD that do not respond to oral iron therapy 
(Bonovas et al., 2016). In our study, patients receiving INFeD or Venofer demonstrated a 
mean increase in hemoglobin of 1.85g/dl±0.64 and 1.31g/dl±0.34, respectively. This 
difference in the average change of hemoglobin level between the two formulations can 
be attributed to dose and time. Specifically, INFeD can restore iron levels in as little as 
one infusion with doses up to 2g, while Venofer is given at around 200mg for multiple 
doses over time. Both formulations are on the BCH formulary and are used routinely. 
Other factors that may influence a provider or patient’s decision for iron therapy is cost 
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and side effects. INFeD costs roughly $4500 for 10 doses, while Venofer costs $688 for 
10 doses (Reinisch et al., 2013). INFeD has been associated with IgE-mediated 
anaphylactic reactions in a small population of users while Venofer is reported to have a 
lower relative risk for severe side effects (Muñoz et al., 2009). Oral iron has also been 
reported to cause nausea, vomiting, and potential disease exacerbation due to the 
unabsorbed iron in the GI lumen forming toxic free hydroxyl radicals via the Fenton 
reaction (Carrier et al., 2001). In our study, we monitored for adverse events in patients 
receiving iron therapy. Patients who received oral ferrous sulfate or Venofer were not 
reported to experience any adverse events during the study period. We did have one 
report of an IBD patient who received INFeD progress to anaphylactoid reaction, which 
was immediately intervened by the inpatient team. That patient, as a result, spent an extra 
night in the inpatient GI service as part of protocol before being cleared for discharge.  
The second aim of the study was to assess the change in HRQOL in IBD patients 
receiving iron therapy. This was measured through the administration of the IMPACT-III 
pediatric questionnaire. The questionnaire score ranges from 35-175 with a higher score 
suggesting a better HRQOL in patients. Currently, there exists more research in HRQOL 
in adult patients with IBD than in the pediatric population. Especially in the context of 
iron therapy affecting HRQOL, the data available is sparse. For our study, the baseline 
HRQOL score was obtained during the patient’s inpatient stay before iron therapy was 
given. The follow-up HRQOL score was taken during their next outpatient visit. Our 
study showed that patients receiving either IV or oral iron therapy had a mean increase in 
score of 11.6±11.4 and 3.8±7.5, respectively, suggesting a better quality of life.  
	35 
Patients who did not have iron studies completed in time or were not treated with 
iron during their inpatient stay due to other illnesses or procedures were followed up with 
their primary GI provider, and the suggestion of iron therapy was made. Patients unable 
to complete the HRQOL questionnaire were still enrolled and data was collected 
primarily via iron studies and chart review.  
The present study has some limitations. Patients receiving iron treatment were 
followed up based on their next outpatient visit, which varied patient to patient. Since 
iron studies could only be requested during those visits, there was no uniform time period 
in which a patient’s iron status was checked. On average, the window to assess the 
change in hemoglobin and iron in our patients was 31.4±15.1 days. Due to this variation, 
a patient’s change in hemoglobin and iron level may not accurately reflect the full benefit 
of iron therapy, especially if more than 30 days elapsed since iron treatment.  
Secondly, the collection of the HRQOL measures did not take place in the same 
environment. The baseline HRQOL was given in the inpatient setting and the follow-up 
usually took place in the outpatient setting. While a few patients unfortunately were 
readmitted and followed up as inpatients, the majority of patients were given the follow-
up questionnaires after discharge, which could affect mood and perception of disease 
since they are no longer in the inpatient setting. This change in environment can 
potentially influence their feeling of well-being and not necessarily reflect the effect of 
iron therapy alone.  
In summary, iron deficiency anemia is a common and important comorbidity in 
patients with IBD, and if left untreated, can decrease quality of life. This is especially 
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pronounced in the pediatric population. Our study demonstrated that the active treatment 
of iron deficiency in a population of pediatric IBD patients increases hemoglobin levels 
significantly more than in patients left untreated. These patients also experienced a better 
quality of life according to the IMPACT-III pediatric questionnaire. As such, it is 
necessary to actively screen and treat patients for IDA and conduct additional studies to 
gain a better understanding of treatment strategies and their efficacy.  
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CONCLUSION 	
 Iron is an essential element for all living organisms. It is typically utilized in 
hemoglobin formation and plays a pivotal role in immune function and neurotransmitter 
metabolism, which maintains cognitive functions such as memory and learning. 	 The objective of this study was to assess the efficacy and safety profile of 
parenteral and enteral iron therapy in a population of iron deficient patients with IBD, as 
well as to determine if parenteral or oral iron can improve hematologic and iron 
parameters (≥ 2 point increase in hemoglobin). Our study suggested that IV iron was 
more efficacious than oral iron in increasing mean hemoglobin values, and resulted in a 
higher HRQOL based on higher IMPACT-III scores. Given the small study population, 
larger, more definitive studies will need to be conducted to further explore the various 
treatments available in treating IDA.   
While in the literature there exists algorithms to advocate which patients should 
receive IV or oral iron therapy, or how often iron levels should be checked, this practice 
has been shown to vary between centers. Before the start of this prospective study, our 
research group showed that roughly 67% of pediatric IBD patients admitted to BCH with 
IDA were not identified or treated for their iron deficiency. Our study showed that there 
was a benefit to patients receiving iron therapy, and that future studies will be required to 
lay the groundwork for a paradigm in which the screening and treatment of IDA in 
patients with IBD is more prevalent.  
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